We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
VistaGen Therapeutics Inc | NASDAQ:VTGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.06% | 4.75 | 4.69 | 4.84 | 4.85 | 4.65 | 4.71 | 194,533 | 22:14:08 |
Nevada
|
000-54014
|
20-5093315
|
(State or other jurisdiction of
incorporation) |
(Commission File Number)
|
(IRS Employer
Identification Number) |
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
VTGN
|
Nasdaq Capital Market
|
Exhibit No.
|
Description
|
|
Press Release issued by VistaGen Therapeutics, Inc., dated November 10, 2021
|
||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
VistaGen Therapeutics, Inc.
|
||
|
|
|
Date: November 10, 2021
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn K. Singh
Chief Executive Officer
|
1 Year VistaGen Therapeutics Chart |
1 Month VistaGen Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions